We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
17 own
5 watching
Current Price
$2.87
$-0.05
(-1.71%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
1,307.15M
52-Week High
9.6373
52-Week Low
2.12
Average Volume
1.11M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,307.15M
52-Week High9.6373
52-Week Low2.12
Average Volume1.11M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
Read More
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
19days ago
The presentation outlines plans for the expansion phase of the study (part B), including the specific tumor indications where 23ME-00610 will be tested for anticancer activitySOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human ...
Globe Newswire
1month ago
Poster to provide details on study design and expansion phase for ongoing Phase 1 study in patients with advanced solid malignanciesSOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a...
PR Newswire
4 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Missfresh Limited - MF SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Missfresh Limited - MF PR Newswire NEW YORK, July 21, 2022 NEW YORK, July 21, 2022 /PRNewswire/ -- Pomerantz LLP...
Zolmax
4 months ago
Stratos Wealth Partners LTD. boosted its position in 23andMe Holding Co. (NASDAQ:ME Get Rating) by 14.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 34,695 shares of the companys stock after buying an ...
Zolmax
5 months ago
HighTower Advisors LLC cut its stake in shares of 23andMe Holding Co. (NASDAQ:ME Get Rating) by 38.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,227 shares of the companys stock after selling 8,...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$2.87
$-0.05
(-1.71%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00